DRC Medicine
Definitive (DA signed)Healthcare · Consumer health / medical devices & IVD · Tokyo, Japan · founded 2007 · 10 employees
- What it is
- Sells HST-treated consumer hygiene merchandise (masks, towels) in Japan and licenses the brand/technology for royalties (two customers were 30%+ and 31% of FY2024/FY2025 revenue); HST sheet is produced under a NON-exclusive license to Shinshu Ceramics' antibacterial patent with DRC's own allergen-adsorption improvement patents on top; future model depends on PMDA medical-device certification of the therapeutic mask and launch of IVD kits.
- What it’s doing now
- Merging with Ribbon (RIBB) — definitive (da signed), announced Jun 30, 2025.
- What you should know
- The real share count puts the effective valuation 18% above the announced $350M. At 920.3× revenue the deal prices it above its listed peers, which trade at 1.32×.
The business, per its filings
SEC primaryDRC Medicine Ltd. (Tokyo, founded 2007, CEO Dr. Marumi Okazaki) sells Hydro Silver Titanium (HST) antibacterial/allergen-adsorbing consumer hygiene products - chiefly masks and towels sold via merchandise sales plus brand-license royalties - and is trying to convert the HST Sheet mask into a certified therapeutic device for seasonal allergic rhinitis after Japan's PMDA DECLINED approval in March 2024; a pipeline of IVD kits (cell-free protein synthesis tech, AI apps) and a mooted acquisition of an ATP-enhancing Parkinson's-drug developer are still pre-commercial. THE FINANCIAL REALITY VS THE STORY: actual revenue is microscopic and shrinking - $0.676M FY2024A to $0.453M FY2025A (FYE Jul-31; ~88% merchandise, rest royalties) and $0.266M in 9M FY2026 (down 30% y/y) - with net losses of $2.16M/$1.68M/$1.61M (FY2024/FY2025/9M FY2026), cash of just $0.284M, ~$5.84M of bank borrowings partly guaranteed by a significant shareholder, a $4.78M shareholders' deficit and an explicit going-concern qualification; yet the merger prices DRC at a $350M pre-money fully-diluted equity value (~772x FY2025 revenue) with pro forma equity ~$422.15M, existing DRC holders keeping ~82.91%, and only ~$50M trust cash (no-redemption case) as the funding story. Post-closing PubCo expects approximately 10 employees.
| Revenue | $0.5M (FY2025A (fiscal year ended July 31, 2025; audited)) |
| Cash | $0.3M |
| Debt | $5.8M |
Source: S-4/A, accession 0001213900-26-080459 · as of Jul 31, 2025 · extraction confidence: high
What the company says about itself
Web research — not auditedSite presents DRC as a 'hybrid bio company' built on the DR.C20 photocatalyst that degrades proteins (allergens, viruses), with university co-research news (Nagasaki, RIKEN, Mahidol, Hokkaido) mostly dated 2020-2022, plus ambitions in drug discovery and malaria eradication; news feed appears stale (latest item Nov 2022), consistent with the filing's picture of a tiny company.
- Markets:
- Pharmaceutical business, medical devices, consumer allergy/infection-control materials; malaria-control research
- Products:
- DR.C20 photocatalyst material (protein-degrading catalyst) fixed onto sheets/fabrics; HAT/HATS protein-degradation technology; anti-allergen masks and consumer collaborations (Kawabe, Ichihiro/Towel Museum group)
- Customers:
- Consumer products via partner companies; research collaborations named: Nagasaki University (99.99% SARS-CoV-2 infectivity reduction claim), RIKEN (spike-protein cleavage), Mahidol University & Hokkaido University (mosquito/malaria control)
None material; site emphasizes research claims (e.g. '99.99% coronavirus reduction') and 2020-2022 news while the S-4/A shows declining sub-$1M revenue, a 2024 PMDA rejection and going-concern doubt - a tone gap, not a factual contradiction.
Source: https://drciyaku.co.jp/ · captured Aug 14, 2026 · marketing claims are reported as claims, never merged into the filed figures above.
The deal it’s entering
DRC Medicine is merging with Ribbon (RIBB), a $49M SPAC currently marked Deal announced and trading at $13.69 against $10.00 in trust per share.
| Headline equity value | $350M |
| Effective valuation (all shares) | $411M+18% vs headline |
| Sponsor promote | 20% |
Structure per SEC accession(s) 0001213900-26-057788, 0001213900-25-060364. How to read these numbers: headline vs effective valuation · what a definitive agreement commits
What exactly is being valued, and at what
Was this deal done at an expensive or a cheap valuation?
SpacBrain’s read on the price
Priced above its listed peers
The deal values DRC Medicine Ltd. at $416.9M, or 920.3× the FY2025A (fiscal year ended July 31, 2025; audited) actual revenue it actually reported. That is 697.2× what the market pays for its closest listed peers (median 1.32×) — an expensive price.
Post-dilution equity + target net debt.
FY2025A (fiscal year ended July 31, 2025; audited) — a reported actual.
920.3× FY2025A (fiscal year ended July 31, 2025; audited) actual revenue. Put another way: $1 of its annual sales is being bought for $920.30.
$1 of their sales costs $1.32 on the open market. Median of 2 listed companies we judged a true comparable, which individually run from 1.15× to 1.49×. Their share prices are from 14 August 2026, not today.
What qualifies this number
- Struck on the post-dilution value of $411.3M, not the announced $350M — new shares handed to the sponsor, warrant holders and the PIPE are part of what public buyers are really paying.
- 8113.T, NNNN, 4967.T, AYTU, WOK, GFCX, 6523.T have no revenue to divide by, so they are shown but left out of the peer median.
The listed companies it is measured against
| Ticker | Company | Mkt cap | EV / revenue | EV / EBITDA | Why it’s comparable |
|---|---|---|---|---|---|
| 8113.T | UNICHARM CORP | — | — | — | Unicharm - Japan's dominant hygiene-products maker (masks, personal care); the scaled version of DRC's consumer mask/hygiene merchandise business. |
| NNNN | Anbio Biotechnology | $1.3B | — | — | Operational comp: Medical Equipment, Supplies & Distribution (NEC); small-cap ($1.3bn); shares ivd, medical, device, drug, products, for with the target's own description; no forward EV/Sales published — counted as a peer, excluded from the median.more ▾less ▴ |
| 4967.T | KOBAYASHI PHARMACEUTICALS | — | — | — | Kobayashi Pharmaceutical - Japanese consumer-healthcare/OTC products company selling branded self-care goods through the same drugstore channels DRC targets.more ▾less ▴ |
| AYTU | Aytu Biopharma Inc | $20M | — | — | Operational comp: Biopharmaceuticals; micro-cap ($20m); shares rhinitis, allergic, deficit, seasonal, sold, are with the target's own description; forward EV/Sales 0.4x.more ▾less ▴ |
| QDEL | QuidelOrtho Corporation | $1.0B | 1.5x | 8.2x | QuidelOrtho - respiratory and allergy point-of-care IVD maker; the listed benchmark for the infectious-disease/allergen IVD kits DRC says it is developing.more ▾less ▴ |
| WOK | WORK Medical Technology Group Ltd | $8M | — | — | Operational comp: Medical Equipment, Supplies & Distribution (NEC); micro-cap ($8m); shares masks, mask, holders, devices, medical, sales with the target's own description; no forward EV/Sales published — counted as a peer, excluded from the median.more ▾less ▴ |
| OSUR | OraSure Technologies, Inc. | $276M | 1.1x | — | OraSure Technologies - small-cap consumer-adjacent point-of-care diagnostics; comparable scale-stage IVD economics. |
| GFCX | GoodFaith Technology Inc | — | — | — | Operational comp: Corporate Financial Services (NEC); shares approval, pre, post, consumer, bank, financial with the target's own description; no forward EV/Sales published — counted as a peer, excluded from the median.more ▾less ▴ |
| 6523.T | PHC HLDGS CORP | — | — | — | PHC Holdings - Tokyo-listed diagnostics and medical-device group; Japanese-listed comp for the medical-device certification path DRC is pursuing. |
Which companies belong on this list is our judgement, and the sentence beside each one is the whole of our reasoning — disagree with it and the verdict above changes. Rows marked context only are shown because they are informative, but they are deliberately left out of the median. The multiples come from listed-company data priced Aug 14, 2026; a private target’s deal multiple is not audited the way theirs are.
Common questions
Is DRC Medicine going public?
DRC Medicine has a signed merger with the SPAC Ribbon (RIBB), announced Jun 30, 2025. Deal status: Definitive (DA signed).
What is DRC Medicine's SPAC deal valuation?
The announced headline equity value is $350M, but counting every share class — founder promote, PIPE and public shares — the effective valuation is $411M, 18% above the headline.
Was DRC Medicine bought at an expensive or a cheap valuation?
The deal values DRC Medicine Ltd. at $416.9M, or 920.3× the FY2025A (fiscal year ended July 31, 2025; audited) actual revenue it actually reported. That is 697.2× what the market pays for its closest listed peers (median 1.32×) — an expensive price.
Does DRC Medicine have revenue?
The filings report a revenue figure of $0.5M (FY2025A (fiscal year ended July 31, 2025; audited)).
Educational content, not investment advice.
- Nanyang Biologics — with RFAI ($1.5B) · pre-revenue
- Talawar Therapeutics — with JATT ($120M) · pre-revenue
- First Choice Healthcare — with WSTN ($650M)
- Veraxa Biotech — with VACH
- Minovia Therapeutics — with LPAA ($180M)